SQI Diagnostics Submits RALI-Dx; IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
with Confirmed COVID-19 Illness TORONTO, April 1, 2021 /PRNewswire/ - SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announces that it has submitted its fully completed clinical and analytical data package to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of its RALI-Dx ™ IL-6 Severity Triage Test. The submission was completed on March 31, 2021. The FDA wi...
Source: biospace.com